Navigation Links
ZEISS Ends Successful Fiscal Year 2012/13
Date:12/12/2013

STUTTGART, Germany, December 12, 2013 /PRNewswire/ --

Revenue Reaches New Record High

ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million). The Industrial Metrology and Medical Technology business groups recorded particularly strong growth. "In fiscal year 2012/13 we reached and partly exceeded our targets. ZEISS put in a good performance despite the challenging business environment and the weakness of the economy at the beginning of the year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss AG. "We made no compromises in our multi-year investment program - the biggest ever in the company's history - but continued to implement it consistently and systematically."

The number of employees increased to 24,623 worldwide. The company increased its expenditure on research and development activities by five percent to EUR 411 million. Investments in property, plant and equipment totaled EUR 245 million.

More information at http://www.zeiss.com/press

ZEISS is an international leader in the fields of optics and optoelectronics. The more than 24,000 employees of ZEISS generated revenue of about 4.2 billion euros in fiscal year 2012/13. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. ZEISS has been contributing to technological progress for more than 160 years. ZEISS develops and produces solutions for the semiconductor, automotive and mechanical engineering industries, biomedical research and medical technology, as well as eyeglass lenses, camera and cine lenses, binoculars and planetariums. ZEISS is present in over 40 countries around the globe with more than 40 production facilities, around 50 sales and service locations and over 20 research and development sites. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).

Press contact
ZEISS Group
Jörg Nitschke, Pressesprecher
Phone +49-07364-20-3242
Email: joerg.nitschke@zeiss.com


'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
2. Carl Zeiss continúa en ruta hacia el crecimiento futuro e inversión
3. Carl Zeiss Continues on Track to Further Growth and Investment
4. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
5. Orexigen Announces Successful Interim Analysis of Contrave Light Study
6. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
7. WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
8. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
9. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Overcoming Regional Marketplace Complexities to Successfully Launch a Global Brand Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Digital Scientists, a software innovation lab specializing in web ... Greenville, South Carolina location. The lab has set up shop at the ... working with South Carolina clients for years from our office here in Atlanta,” explains ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... ... 24, 2017 , ... The iaedp Foundation, the premier provider of educational programs ... suffering from the full spectrum of disordered eating, announced today that the 2017 Symposium ... all 50 states and several countries converged on the Green Valley Resort in Las ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
Breaking Medicine News(10 mins):